CEO Communication 2018
Leading the way as a premium supplier for better diagnosis of Helicobacter pylori infection
We aim to be the leading premium supplier within Urea Breath Test market worldwide. This requires focusing on building trust and delivering quality products that ads value for our customers. To accomplish this, we continuously invest in competence and resources internally, with extra focus on Quality Assurance & Regulatory Affairs. Kibion is since several years already a ISO 13485 certified company, which is something that we value highly.
The new version of ISO 13485 places greater emphasis on risk management and risk-based decisions making processes to ensure safer products for patients across the world. The new version also reflects the increased regulatory requirements for organizations across the medical device supply chain. I am pleased to announce that Kibion was audited by TÜV Süd in May and has been approved in accordance to ISO 13485:2016 for the coming period.
Continuous learning and improvement
We always try to do things better. Even though our instruments offer superior quality in design and performance, we also continue to invest in our service and support functions. In addition, we strive to further develop our products to meet the customer’s specific requirements. One example is the continuous upgrading of our instruments’ software solutions to meet the customers’ needs. Another example is our efforts to fin opportunities to further improve the usability of Kibion’s innovative instruments and our services. This is demonstrated in Kibion ‘s innovative instrument Kibion® Dynamic with its new features that are apricated by customers and bring substantial value for health care professionals. We could also add the development a Multisampler allowing our clients to analyze 120 tests in a shorter time.
Strategic geographical expansions
As a leading company in the gastro market, we are committed to live our vision “To be first in mind, first in choice”. Kibion already has representation in over 60 countries, mainly in the Middle East and the EU, and we have the goals and strategy in place for additional global expansion and growth. Last year we added Algeria, Morocco and Vietnam as key markets, and our ambition is to expand into new exciting geographical markets moving forward. I hope that Kibion soon will be able to communicate about new collaborations that make it possible for our premium products to be available in more geographic markets reaching even more patients in need for diagnosis and treatment of Helicobacter pylori.
At the end of the day, our ambition is to bring value – not only to our distributors by providing the end users with our instruments and test – but also to the many patients who benefit from our user-friendly breath tests, and to health authorities offering a solid solution to reduce the impact of Helicobacter pylori and cancer treatment costs. This is important to us, since we are committed to work for a better gastro healthcare worldwide.
Welcome to contact us and we will be happy to tell you more about our products and services.
Mathieu Duroselle, Vice President International Pharma & Medical device and CEO, Kibion AB; which is a part of Laboratoires Mayoly Spindler. www.mayoly-spindler.fr